Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA warns Platinum Strategies

This article was originally published in The Tan Sheet

Executive Summary

FDA warns Platinum Strategies that several of its weight-loss products marketed as dietary supplements are unapproved prescription drugs because they include sibutramine - the active pharmaceutical ingredient in the obesity drug Meridia. In a Sept. 23 warning letter, FDA listsPineapple Fat Reducing Slimming Capsule, Tomato Slimming and other products as unapproved new prescription drugs. The agency also notes the firm's Web site has offered other products that contain sibutramine, including Starcaps. Several NFL players alleged Starcaps, made by Balanced Health Products, contained undeclared bumetanide, a diuretic banned by the league (1"The Tan Sheet" Dec. 1, 2008)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103519

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel